Regadenoson: Review of its established role in myocardial perfusion imaging and emerging applications

Guru Palani, Karthikeyan Ananthasubramaniam

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


Myocardial perfusion imaging is a well-established noninvasive modality for the diagnosis and prognosis of coronary artery disease. The pharmacologic stress agents adenosine and dipyridamole are widely used in imaging studies, but cause undesirable side effects, like atrioventricular block and bronchospasm, due to their nonselective adenosine receptor activation. Furthermore, the mode of administration of these agents as a bolus infusion is less preferred. Regadenoson, an A2A adenosine receptor selective pharmacologic stress agent was approved in 2008 and is widely used instead of adenosine and dipyridamole. This article reviews regadenosons structure, mechanism of action, advantages over adenosine and dipyridamole, and its role in various patient populations undergoing stress perfusion imaging. Emerging applications where regadenoson could be of potential use are also explored.

Original languageEnglish (US)
Pages (from-to)42-48
Number of pages7
JournalCardiology in Review
Issue number1
StatePublished - Jan 2013
Externally publishedYes


  • adenosine
  • chronic kidney disease
  • chronic obstructive pulmonary disease
  • coronary artery disease
  • coronary flow reserve
  • dipyridamole
  • pharmacologic stress myocardial perfusion imaging
  • regadenoson
  • stress echocardiography


Dive into the research topics of 'Regadenoson: Review of its established role in myocardial perfusion imaging and emerging applications'. Together they form a unique fingerprint.

Cite this